Chemours (CC) Liabilities and Shareholders Equity (2014 - 2026)

Chemours has reported Liabilities and Shareholders Equity for 13 years, with the latest figure at $7.2 billion in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 4.18% year-over-year to $7.2 billion in Q2 2026; TTM through Jun 2026 was $29.3 billion, a 1.54% decrease from a year earlier, with the FY2025 full-year figure at $7.4 billion, down 1.69% from the prior year.
• Liabilities and Shareholders Equity was $7.2 billion for Q2 2026 at Chemours, down from $7.3 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $8.2 billion in Q4 2023, with the low at $7.2 billion in Q2 2026.
• Average Liabilities and Shareholders Equity over 5 years is $7.6 billion, with a median of $7.5 billion recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity gained 7.87% in 2023, then declined 8.88% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $7.6 billion in 2022, then advanced by 7.87% to $8.2 billion in 2023, then dropped by 8.88% to $7.5 billion in 2024, then fell by 1.69% to $7.4 billion in 2025, then retreated by 3.14% to $7.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $7.2 billion (Q2 2026), $7.3 billion (Q1 2026), and $7.4 billion (Q4 2025), per Business Quant data.